GIPC1: A Protein Involved in Cell Signaling, Tissue Repair and Inflammation

Target Name: GIPC1

NCBI ID: G10755

GIPC1

GIPC1: A Protein Involved in Cell Signaling, Tissue Repair and Inflammation

GIPC1 (PDZ domain-containing protein GIPC1) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the PDZ (Philosophical Society of outstanding scientists) domain family, which is known for its role in the regulation of signaling pathways. GIPC1 has been shown to play a role in a variety of physiological processes, including cell signaling, tissue repair, and inflammation.

One of the unique features of GIPC1 is its ability to interact with other proteins that contain the PDZ domain. This interaction allows GIPC1 to regulate the activity of these other proteins, which can lead to a wide range of cellular and tissue effects. For example, GIPC1 has been shown to interact with the protein Shc1, which is a key regulator of the T-cell receptor signaling pathway. When GIPC1 and Shc1 are together, they can enhance the activity of the T-cell receptor, which is important for the development and activation of T-cells.

Another example of the impact of GIPC1 is its role in tissue repair. When cells are damaged or destroyed, GIPC1 can help to repair the damage by promoting the growth and proliferation of surrounding cells. This is shown in studies where GIPC1 has been shown to be involved in the repair of muscle tissue after injury, where it can help to promote the growth and regeneration of new muscle cells.

GIPC1 also plays a role in the regulation of inflammation. When the body is exposed to an invading agent, such as a bacteria or a virus, GIPC1 can help to regulate the immune response. It does this by interacting with the protein NF-kappa-B, which is a key regulator of inflammation. When GIPC1 and NF-kappa-B are together, they can inhibit the activity of NF-kappa-B, which can help to reduce inflammation.

In addition to its role in regulation of signaling pathways, GIPC1 has also been shown to be involved in the regulation of cellular processes such as cell adhesion, migration and invasion.

GIPC1 is also a potential drug target. Its ability to interact with other proteins that contain the PDZ domain, as well as its role in tissue repair and inflammation, makes it an attractive target for small molecule inhibitors. Several compounds have been shown to inhibit the activity of GIPC1, and further studies are being conducted to determine the most effective and safe methods of targeting this protein.

GIPC1 is also a potential biomarker for a variety of diseases. Its role in tissue repair and inflammation makes it an attractive target for diagnostic tests for diseases such as cancer, autoimmune diseases and neurodegenerative diseases.

In conclusion, GIPC1 is a protein that plays a critical role in a variety of physiological processes in the body. Its ability to interact with other proteins that contain the PDZ domain and its role in tissue repair and inflammation make it an attractive target for small molecule inhibitors and potential biomarkers. Further studies are needed to fully understand the function of GIPC1 and its potential as a drug target and biomarker.

Protein Name: GIPC PDZ Domain Containing Family Member 1

Functions: May be involved in G protein-linked signaling

The "GIPC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GIPC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets